Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report

Crizotinib, a small molecular tyrosine kinase inhibitor, manifests dramatic responses in patients with non-small cell lung cancer with echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements. ALK gene point mutation is the primary mechanism of acquired c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ling, Li, Yunxia, Zhang, Shaohong, Gao, Chen, Nie, Keke, Ji, Youxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994555/
https://www.ncbi.nlm.nih.gov/pubmed/29951342
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994555/
https://www.ncbi.nlm.nih.gov/pubmed/29951342
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0003

Ejemplares similares